<DOC>
	<DOCNO>NCT01043601</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy inhale formoterol fumarate ( 7.2 9.6 µg ex-actuator ) compare placebo Foradil Aerolizer patient moderate severe chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Efficacy Safety Two Doses Formoterol Fumarate MDI ( PT005 ) Patients With Stable Chronic Obstructive Pulmonary Disease ( COPD ) , Compared Foradil® Aerolizer® Active Control</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Key Signed write informed consent 40 80 year age Fluency write spoken English Females nonchild bear potential female child bear potential negative pregnancy test ; acceptable contraceptive method Current/former smoker least 10 packyear history cigarette smoke A measure post bronchodilator FEV1/FVC ratio &lt; = 0.70 A measure post bronchodilator FEV1 &gt; = 750ml 30 % predict &lt; = 80 % predict normal value Competent use inhalation device Key Women pregnant lactate Primary diagnosis asthma Alpha1 antitrypsin deficiency cause COPD Active pulmonary disease Prior lung volume reduction surgery Abnormal chest Xray ( CT scan ) due presence COPD Hospitalized due poorly control COPD within 12 week Screening Poorly control COPD , define occurrence acute worsen COPD require corticosteroid antibiotic acute worsen COPD require treatment prescribed physician within 6 week screen screen visit 2 Lower respiratory tract infection require antibiotic within 6 week screen Clinically significant medical condition preclude participation study ( e.g . clinically significant abnormal ECG uncontrolled hypertension ) Positive Hepatitis B surface antigen Hepatitis C antibody Cancer complete remission least 5 year History hypersensitivity beta2agonists study drug component History severe milk protein allergy Known suspect history alcohol drug abuse Medically unable withhold short act bronchodilator 8hours Use prohibit medication prior screen study specify protocol Receiving longtermoxygen nocturnal oxygen therapy &gt; 12 hour day Participation acute phase pulmonary rehabilitation within 4 week screen enter acute phase pulmonary rehabilitation program study Unable comply study procedure Prior participation Pearl PT005 study Requires use spacer due poor handtobreath coordination</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>